Richmond Pharmacology continually evaluates the processes we undertake and examine whether they deliver maximum value to trial sponsors while not compromising quality or patient safety.

One of the ways we do this is through the use of adaptive trial protocols which enables the safe modification of a trial’s course in accordance with pre-specified rules in the protocol. Modifications may include for example, the need to change the patient sample size, review the data collected and evaluate which groups of patients are responding.

One of the reasons why the UK is an outstanding location to deliver clinical studies is that the regulator - the MHRA - embrace and support the use of adaptive trial protocols. This allows Contract Research Organisation’s such as us the ability to operate more flexibly and to take decisions faster; ensuring that trials can reach their end points sooner and the most promising therapeutics move to the next stage more quickly.

To read the full article, click here. If you would like to learn more about the value of adaptive protocols in clinical trials please contact us

Latest news

Red4Research Blog – Alan’s Story

June 24, 2025
#Red4Research is a global initiative that recognises the essential role of clinical research in improving treatment, outcomes, and the future of medicine.
Read more

Richmond Appoints Lisa Campbell as Director of Regulatory Strategy

April 23, 2025
Richmond Pharmacology is pleased to announce the appointment of Lisa Campbell as Director of Regulatory Strategy
Read more

Events

BIO International Convention 2025

16-19 June 2025
Richmond Pharmacology will be attending the BIO International Convention 2025 in Boston, connecting with biotech innovators at Booth 765.
View event